Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice
暂无分享,去创建一个
Wim Van Biesen | Raymond Vanholder | Mustafa Arici | Thomas Benzing | Ron T. Gansevoort | Kai-Uwe Eckardt | Carmine Zoccali | Francesco Emma | Roser Torra | Bertrand Knebelmann | Alberto Ortiz | Christiane Drechsler | G. Capasso | W. van Biesen | T. Benzing | C. Zoccali | A. Ortiz | Z. Massy | R. Vanholder | A. Więcek | R. Gansevoort | K. Eckardt | B. Knebelmann | O. Devuyst | A. Ong | R. Torra | F. Schaefer | F. Emma | A. Covic | C. Drechsler | M. Arıcı | Y. Le Meur | H. Birn | Franz Schaefer | Adrian Covic | Giovambattista Capasso | Andrzej Więcek | Olivier Devuyst | Ziad A. Massy | Henrik Birn | Yannick Le Meur | Albert C.M. Ong
[1] K. Bae,et al. A comparison of ultrasound and magnetic resonance imaging shows kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease , 2015, Kidney international.
[2] angesichts der Corona-Pandemie,et al. UPDATE , 1973, The Lancet.
[3] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[4] C. Férec,et al. Type of PKD1 mutation influences renal outcome in ADPKD. , 2013, Journal of the American Society of Nephrology : JASN.
[5] Paul Robinson,et al. A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease , 2015, BMC Nephrology.
[6] K. Bae,et al. Imaging for the prognosis of autosomal dominant polycystic kidney disease , 2010, Nature Reviews Nephrology.
[7] R. Gansevoort,et al. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. , 2016, Clinical journal of the American Society of Nephrology : CJASN.
[8] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.
[9] X. Lens,et al. Comparison between siblings and twins supports a role for modifier genes in ADPKD. , 2004, Kidney international.
[10] J. Grantham,et al. Why kidneys fail in autosomal dominant polycystic kidney disease , 2011, Nature Reviews Nephrology.
[11] A. Cheung,et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[12] G. Navis,et al. Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[13] T. Mochizuki,et al. Renal disease progression in autosomal dominant polycystic kidney disease , 2012, Clinical and Experimental Nephrology.
[14] P. Watkins,et al. Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database , 2015, Drug Safety.
[15] B. Kasiske,et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. , 2015, Kidney international.
[16] G. Beck,et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. , 1994, The New England journal of medicine.
[17] S. Strandgaard,et al. Estimating Glomerular Filtration Rate Using the New CKD-EPI Equation and Other Equations in Patients with Autosomal Dominant Polycystic Kidney Disease , 2009, American Journal of Nephrology.
[18] M. Chonchol,et al. Predictors of autosomal dominant polycystic kidney disease progression. , 2014, Journal of the American Society of Nephrology : JASN.
[19] G. Beck,et al. The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease , 1994 .
[20] Douglas Landsittel,et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. , 2012, Clinical journal of the American Society of Nephrology : CJASN.
[21] Eiji Higashihara,et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. , 2012, The New England journal of medicine.
[22] G. Brosnahan,et al. Volume progression in polycystic kidney disease. , 2006, The New England journal of medicine.
[23] J. García Rodríguez,et al. [Polycystic Kidney Disease]. , 2005, Actas urologicas espanolas.
[24] Oliver Senn,et al. Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. , 2009, Kidney international.
[25] G. Walz,et al. Autosomal dominant polycystic kidney disease: the changing face of clinical management , 2015, The Lancet.
[26] J. Coresh,et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. , 2014, JAMA.
[27] D. Hems,et al. Stimulation by vasopressin of glycogen breakdown and gluconeogenesis in the perfused rat liver. , 1973, The Biochemical journal.
[28] C. Férec,et al. The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease. , 2016, Journal of the American Society of Nephrology : JASN.
[29] Brenda R. Hemmelgarn,et al. Notice , 2012, Kidney International Supplements.
[30] A. Chapman,et al. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. , 2005, Clinical journal of the American Society of Nephrology : CJASN.
[31] G. Remuzzi,et al. Rare inherited kidney diseases: challenges, opportunities, and perspectives , 2014, The Lancet.
[32] C. Wanner,et al. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. , 2014, Kidney international.
[33] Harold I Feldman,et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. , 2012, The New England journal of medicine.
[34] J P Kriss,et al. Limitations of creatinine as a filtration marker in glomerulopathic patients. , 1985, Kidney international.
[35] A. Paterson,et al. Family history of renal disease severity predicts the mutated gene in ADPKD. , 2009, Journal of the American Society of Nephrology : JASN.
[36] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.
[37] Ajay V. Srivastava,et al. Autosomal dominant polycystic kidney disease. , 2014, American family physician.
[38] J. Glockner,et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. , 2011, Kidney international.
[39] T. Steinman. Polycystic kidney disease: a 2011 update , 2012, Current opinion in nephrology and hypertension.
[40] Bradley J Erickson,et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. , 2015, Journal of the American Society of Nephrology : JASN.
[41] J. D. de Fijter,et al. Estimation of total kidney volume in autosomal dominant polycystic kidney disease. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[42] N. Perico,et al. Measuring and Estimating GFR and Treatment Effect in ADPKD Patients: Results and Implications of a Longitudinal Cohort Study , 2012, PloS one.
[43] A Fournier,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.
[44] S. Bakker,et al. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease. , 2013, Kidney international.